Impact of age at diagnosis on prostate cancer treatment and survival

Journal of Clinical Oncology

Volumn 29, Issue 2, 2011, Pages 235-241

  Bechis, Seth K ^a   Carroll, Peter R ^a   Cooperberg, Matthew R ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGE DETERMINATION; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; BRACHYTHERAPY; CANCER SURVIVAL; CANCER THERAPY; COMORBIDITY; CONSERVATIVE TREATMENT; CRYOTHERAPY; EXTERNAL BEAM RADIOTHERAPY; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; WATCHFUL WAITING;

AGE FACTORS; AGED; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 79951989027     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.30.2075     Document Type: Article

References (40)

1. Crawford ED: Epidemiology of prostate cancer. Urology 62:3-12, 2003
2. Minino AM, Smith BL: Deaths: Preliminary data for 2000. National Vital Statistics Reports, Vol 49, No. 12. Hyattsville, MD, National Center for Health Statistics, 2001, pp 1-40. http://www.cdc.gov/nchs/data/nvsr/nvsr49/nvsr49-12. pdf
3. Jemal A, Siegel R, Xu J, et al: Cancer statistics, 2010. CA Cancer J Clin 60:277-300, 2010
4. Heinzer H, Steuber T: Prostate cancer in the elderly. Urol Oncol 27:668-672, 2009
5. Schröder FH, Hugosson J, Roobol MJ, et al: Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 360:1320-1328, 2009
6. Andriole GL, Crawford ED, Grubb RL 3rd, et al: Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 360:1310-1319, 2009
7. U.S. Preventive Services Task Force: Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 149:185-191, 2008
8. Richstone L, Bianco FJ, Shah HH, et al: Radical prostatectomy in men aged > or = 70 years: Effect of age on upgrading, upstaging, and the accuracy of a preoperative nomogram. BJU Int 101: 541-546, 2008 (Pubitemid 351199287)
9. Cooperberg MR, Lubeck DP, Meng MV, et al: The changing face of low-risk prostate cancer: Trends in clinical presentation and primary management. J Clin Oncol 22:2141-2149, 2004 (Pubitemid 41095147)
10. Schwartz KL, Alibhai SM, Tomlinson G, et al: Continued undertreatment of older men with localized prostate cancer. Urology 62:860-865, 2003 (Pubitemid 37421232)
11. Townsley C, Pond GR, Peloza B, et al: Analysis of treatment practices for elderly cancer patients in Ontario, Canada. J Clin Oncol 23:3802-3810, 2005
12. Konety BR, Cowan JE, Carroll PR: Patterns of primary and secondary therapy for prostate cancer in elderly men: Analysis of data from CaPSURE. J Urol 179:1797-1803, 2008; discussion 1803
13. Ketchandji M, Kuo YF, Shahinian VB, et al: Cause of death in older men after the diagnosis of prostate cancer. J Am Geriatr Soc 57:24-30, 2009
14. Manton KG, Vaupel JW: Survival after the age of 80 in the United States, Sweden, France, England, and Japan. N Engl J Med 333:1232-1235, 1995
15. Stangelberger A, Waldert M, Djavan B: Prostate cancer in elderly men. Rev Urol 10:111-119, 2008
16. Greco KA, Meeks JJ, Wu S, et al: Robotassisted radical prostatectomy in men aged > or = 70 years. BJU Int 104:1492-1495, 2009
17. Marr PL, Elkin EP, Arredondo SA, et al: Comorbidity and primary treatment for localized prostate cancer: Data from CaPSURE. J Urol 175: 1326-1331, 2006
18. Lubeck DP, Litwin MS, Henning JM, et al: The CaPSURE database: A methodology for clinical practice and research in prostate cancer - CaPSURE Research Panel. Cancer of the Prostate Strategic Urologic Research Endeavor. Urology 48:773-777, 1996 (Pubitemid 26398700)
19. Cooperberg MR, Broering JM, Litwin MS, et al: The contemporary management of prostate cancer in the United States: Lessons from the cancer of the prostate strategic urologic research endeavor (CapSURE), a national disease registry. J Urol 171: 1393-1401, 2004 (Pubitemid 38365382)
20. Cooperberg MR, Vickers AJ, Broering JM, et al: Comparative risk-adjusted mortality outcomes following primary surgery, radiotherapy, or androgen-deprivation therapy for localized prostate cancer. Cancer 116:5226-5234, 2010
21. Kattan MW, Eastham JA, Stapleton AM, et al: A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst 90:766-771, 1998 (Pubitemid 28259189)
22. Cooperberg MR, Broering JM, Carroll PR: Risk assessment for prostate cancer metastasis and mortality at the time of diagnosis. J Natl Cancer Inst 101:878-887, 2009
23. Fine JP, Gray RJ: A proportional hazards model for the subdistribution of competing risk. J Am Statist Assoc 94:496-509, 1999
24. Alibhai SM, Leach M, Tomlinson G, et al: 30-day mortality and major complications after radical prostatectomy: Influence of age and comorbidity. J Natl Cancer Inst 97:1525-1532, 2005 (Pubitemid 41631952)
25. Middleton RG, Thompson IM, Austenfeld MS, et al: Prostate Cancer Clinical Guidelines Panel Summary report on the management of clinically localized prostate cancer: The American Urological Association. J Urol 154:2144-2148, 1995
26. Keating NL, O'Malley AJ, Smith MR: Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 24: 4448-4456, 2006 (Pubitemid 46630983)
27. Kumar RJ, Barqawi A, Crawford ED: Adverse events associated with hormonal therapy for prostate cancer. Rev Urol 7:S37-S43, 2005 (suppl 5)
28. Fitzpatrick JM: Management of localized prostate cancer in senior adults: The crucial role of comorbidity. BJU Int 101:16-22, 2008 (suppl 2)
29. Alibhai SM, Naglie G, Nam R, et al: Do older men benefit from curative therapy of localized prostate cancer? J Clin Oncol 21:3318-3327, 2003
30. Jang TL, Bekelman JE, Liu Y, et al: Physician visits prior to treatment for clinically localized prostate cancer. Arch Intern Med 170:440-450, 2010
31. Yan Y, Carvalhal GF, Catalona WJ, et al: Primary treatment choices for men with clinically localized prostate carcinoma detected by screening. Cancer 88:1122-1130, 2000 (Pubitemid 30127674)
32. Fleshner N, Rakovitch E, Klotz L: Differences between urologists in the United States and Canada in the approach to prostate cancer. J Urol 163:1461-1466, 2000 (Pubitemid 30226296)
33. Shahinian VB, Kuo YF, Freeman JL, et al: Determinants of androgen deprivation therapy use for prostate cancer: Role of the urologist. J Natl Cancer Inst 98:839-845, 2006 (Pubitemid 43932049)
34. Cooperberg MR, Broering JM, Carroll PR: Time trends and local variation in primary treatment of localized prostate cancer. J Clin Oncol 28:1117-1123, 2010
35. Bubolz T, Wasson JH, Lu-Yao G, et al: Treatments for prostate cancer in older men: 1984-1997. Urology 58:977-982, 2001
36. Walter LC, Bertenthal D, Lindquist K, et al: PSA screening among elderly men with limited life expectancies. JAMA 296:2336-2342, 2006 (Pubitemid 44749361)
37. Konety BR, Cooperberg MR, Carroll PR: Are age-based criteria the best way to determine eligibility for prostate cancer screening? Ann Intern Med 150:220-221, 2009; author reply 221-222
38. Lu-Yao GL, Albertsen PC, Moore DF, et al: Outcomes of localized prostate cancer following conservative management. JAMA 302:1202-1209, 2009
39. Walz J, Gallina A, Perrotte P, et al: Clinicians are poor raters of life-expectancy before radical prostatectomy or definitive radiotherapy for localized prostate cancer. BJU Int 100:1254-1258, 2007 (Pubitemid 350043902)
40. Walz J, Suardi N, Shariat SF, et al: Accuracy of life tables in predicting overall survival in patients after radical prostatectomy. BJU Int 102:33-38, 2008 (Pubitemid 351799455)